Time trends of rates of HCV diagnoses, HCV infections and of follow-up HCV tests, 2004–2011.

<p>Time trends of rates of HCV diagnoses, HCV infections and of follow-up HCV tests, 2004–2011.</p

Sociodemographic characteristics of 4124 patients with follow-up HCVtest or more than two years of follow-up: prevalence of repeated HCV tests and multivariable logistic regression for the odds ratio (OR) of having a subsequent HCV serology.

<p>Sociodemographic characteristics of 4124 patients with follow-up HCVtest or more than two years of follow-up: prevalence of repeated HCV tests and multivariable logistic regression for the odds ratio (OR) of having a subsequent HCV serology.</p

Rates and associated risk factors of HCV infection.

<p>*The table shows all the variables included in the final multivariables models.</p><p>Rates and associated risk factors of HCV infection.</p

Evolution of follow-up HCV testing rates, of HCV diagnosis rates and of HCV infection rates (per 100 person-years).

<p>Evolution of follow-up HCV testing rates, of HCV diagnosis rates and of HCV infection rates (per 100 person-years).</p

Lipid, hepatic and renal profiles from baseline to 48 weeks.

<p>Lipid, hepatic and renal profiles from baseline to 48 weeks.</p

Baseline characteristics of the study population.

<p>Baseline characteristics of the study population.</p

Ad hoc Kaplan-Meier curve.

<p>Numbers represent the cumulative number of patients at risk of treatment failure at 12, 24, 36 and 48 weeks.</p

Box-plot representation of lipid, hepatic, and renal profiles from baseline to 48 weeks.

<p>Numbers in parenthesis indicate number of patients used to calculate average values at each time point.</p

Study flowchart.

<p>Of the 9 patients who experienced protocol-defined virological failure, resistance testing was performed in 7 of the 8 patients with a viral load of more than 1,000 copies/m. Mutations compromising RAL, ABC, or 3TC were detected in 6 patients (1.3%). All 3 drugs were involved in 4 patients (0.8%). The mutations included NRTI-resistance mutations (K65R, K70T, L74V, M184V, and T215F) and INSTI resistance mutations (N155H, L163E, and G163H). Previous genotyping showed that 2 of these patients harbored pre-existing NRTI resistance mutations (K65R, K70Q/T, L74I/V, and M184V) before switching to RAL+ABC/3TC. Four of the patients with protocol-defined virological failure were taking RAL once daily following the off-label dosage indication [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0198768#pone.0198768.ref011" target="_blank">11</a>], with pre-existing NRTI resistance mutations in 1 of them.</p